Open Nav

Enlil Therapeutics

  • Alexey Bazarov, Enlil Therapeutics

Introduce Enlil to potential investors, partners and collaborators.

  • Date:Thursday, October 18
  • Time:2:30 PM - 2:45 PM
  • Room:Olympic
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Enlil Therapeutics was created to develop a first-in class treatment for idiopathic pulmonary fibrosis, an invariably fatal lung disease affecting 100,000 patients in the U.S. alone. In contrast to the two FDA-approved IPF treatments currently available, pirfenidone and nintedanib, our treatment is intended to cure, not merely delay, disease progression. Our initial focus is on a subset of IPF patients with mutations in RNA subunit of telomerase (hTR). The addressable market for this patient population is estimated to be 150-400M a year in the U.S. alone. We will introduce an adeno-associated virus vector expressing a wild-type copy of hTR into lung epithelial cells of IPF patients, restoring normal telomerase activity and reversing the disease progression. Enlil will further develop treatments for IPF caused by other telomere-related genes, as well as for the other telomere-related conditions.
  • Company Website:n/a
  • Company HQ City:Fremont
  • Company HQ Country:United States
  • Company HQ State:California                  
  • CEO/Top Company Official:Alexey Bazarov
  • Year Founded:2017
  • Main Therapeutic Focus:Respiratory
  • Lead Product in Development :RNA subunit of telomerase in AAV-based vector
  • Development Phase of Primary Product:Discovery
  • Additional Information/Comments:We believe that Enlil therapeutics is an excellent investment opportunity: our company is comparable to a number of companies developing AAV-based therapies that were recently acquired. Among those are Bamboo therapeutics focusing on rare neuromuscular disease treatments, which was acquired by Pfizer for $193M upfront, and additional $495M after Bamboo completes certain milestones. The acquisition occurred prior to the start of the clinical trials. Another example is Dimension therapeutics, a company developing AAV-based treatment of hemophilia. After it has initiated phase 1/2 clinical trials, it was acquired by Ultragenyx for $156.3M. The first U.S. approval of an AAV gene therapy correcting a genetic defect occurred on October 2017, when FDA advisory committee recommended approval of investigational LUXTURNA™ (voretigene neparvovec), developed by Spark therapeutics, for patients with biallelic RPE65-mediated inherited retinal disease. LUXTURNA is priced at 850K/treatment.
  • Total Amount Raised to Date, In All Rounds:0
Alexey Bazarov
Enlil Therapeutics